|Treatments of Sjogren's: Overview
Treatments for Dry Eyes
Treatments for Dry Mouth
|Treatment for Fatigue
Treatment for Renal Involvement
Treatments for Sjogren's may consist of therapies aimed at relieving specific symptoms, such as dry eyes or dry mouth, or targeted at trying to control the underlying disease process.
Clinical Trials: Sjögren's Syndrome. CenterWatch
Use of Biologics in Sjögren's Syndrome. In this review, we summarize the current evidence regarding B–cell targeted and anti–TNF therapies and provide an overview of promising drugs in the pipeline. Rheumatic Disease Clinics, 06/21/2016. (Also see Biologic Agents)
Safety of treatments for primary Sjögren’s syndrome. Synthetic DMARDs have not shown much efficacy in earlier studies, while biologic DMARDs show promising results regarding efficacy and cause mostly mild adverse events. PubMed, Expert Opin Drug Saf, 01/25/2016. (Also see DMARDs)
Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome (SS): the BELISS open-label phase II study. Long–term treatment with belimumab may be beneficial in SS. PubMed, Rheumatology, 08/07/2015.
Treatment with belimumab restores B cell subsets and their expression of B cell activating factor (BAFF) receptor in patients with primary Sjogren's syndrome (pSS). Targeting BAFF with belimumab is successful in normalizing B cell frequency, phenotype and functions in pSS. PubMed, Rheumatology (Oxford), 03/03/2015. (Also see B Cells and T Cells)
Advances in the understanding and treatment of systemic complications in Sjögren's syndrome. Dryness of the mucosal surfaces is the pivotal, but not only, clinical involvement that characterizes primary Sjögren's syndrome. PubMed, Curr Opin Rheumatol, 2014 Sep;26(5):520-7.
Rituximab (RTX) in primary Sjögren's (pSS) syndrome: a ten-year journey. The good results observed after RTX treatment in pSS should represent the starting point to develop evidence-based guidelines for the use of biologic therapy in this disease. PubMed, Lupus, 2014 Aug 5.
Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (pSS) open-label proof of concept ASAP study). Abatacept is effective, safe and well tolerated. It results in improved disease activity, laboratory parameters, fatigue and health-related quality of life in patients with early and active pSS. PubMed, Ann Rheum Dis, 2014 Jan 28.
An innovative treatment for dry eyes. Could an exciting new procedure - involving the heating of the inside of the eyelids - cure dry eyes? The Telegraph, 02/09/2015.
Dry Eyes: Artificial Tears, Dry Eyes, Tears Naturale, Refresh, Refresh Plus, HypoTears, Lacrisert artificial tear inserts.
Gen-Teal Gel by CIBA Vision is an over-the-counter gel for dry eyes. It is best used at night, or along with liquid drops, as it can cause blurriness.
Dry Mouth: Biotene products such as toothpaste, mouthwash, and gel; Salivert, Optimoist, Saliva Substitute, Moi-Stir, and Salix Lozenges.
Evoxac. This medication is used to treat symptoms of dry mouth due to Sjogren's Syndrome. MedicineNet.
Scleroderma Dental Involvement. Systemic scleroderma sometimes affects the mouth, teeth, jaw, and gums. It can cause the mouth to shrink, tooth loss, mouth sores, dry mouth, and jaw pain from TMJ. ISN.
Microstomia (Small Mouth)
Photos of Dental Involvement
Stories of Scleroderma Dental
Taste and Smell
Tongue and Oral Cancers
Xerostomia (Dry Mouth)
A possible genetic association with chronic fatigue in primary Sjögren's syndrome: a candidate gene study. More research on genetic associations with fatigue is warranted. SpringerLink, Rheumatology International February 2014, Volume 34, Issue 2, pp 191-197.
Kidney Failure. Lifelong efforts to control blood pressure and diabetes may be the best way to prevent chronic kidney disease and its progression to kidney failure. Usually, kidney function gradually decreases over time. MedicineNet.com.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: